Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors

G. Varuni Kondagunta, Jennifer Bacik, Lawrence Schwartz, Joel Sheinfeld, Dean Bajorin, Jacqueline Vuky, Stephanie Marion, Madhu Mazumdar, George J. Bosl, Robert J. Motzer

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m2/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.

Original languageEnglish (US)
Pages (from-to)177-179
Number of pages3
JournalInvestigational New Drugs
Volume22
Issue number2
DOIs
StatePublished - Apr 1 2004

Keywords

  • Cisplatin-refractory
  • Germ cell tumor
  • Nonseminoma
  • Phase II
  • Temozolomide

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors'. Together they form a unique fingerprint.

  • Cite this

    Kondagunta, G. V., Bacik, J., Schwartz, L., Sheinfeld, J., Bajorin, D., Vuky, J., Marion, S., Mazumdar, M., Bosl, G. J., & Motzer, R. J. (2004). Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors. Investigational New Drugs, 22(2), 177-179. https://doi.org/10.1023/B:DRUG.0000011794.21608.59